美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物科技指數ETF-iShares Nasdaq

202.40

+0.40000.20%

盤後：202.00-0.4000-0.20%19:51 EDT

成交量：109.88萬

成交額：2.23億

市值：103.12億

市盈率：32.07

高：204.16

開：202.49

低：200.98

收：202.00

52周最高：217.12

52周最低：138.79

股本：5,095.00萬

流通股本：5,095.00萬

量比：0.64

換手率：2.16%

股息：0.40

股息率：0.20%

每股收益(TTM):6.31

每股收益(LYR):35.34

淨資產收益率：24.54%

總資產收益率：0.10%

市淨率：1.27

市盈率(LYR):5.73

資料載入中...

總覽公司新聞資訊公告

藥代違規進入診療區域！湘雅二醫院發藥品「停用函」，艾力斯、賽諾菲、安進、康蒂尼四藥企上「黑榜」

TScan Therapeutics披露：安進將終止與其研究合作及許可協議

吉利德科學(GILD)股票8月18日盤中上漲3.14%：背後推手曝光

TradingKey中文

argenx SE(ARGX)股票8月17日盤中上漲16.67%：關鍵驅動因素揭曉

TradingKey中文

EyePoint股價料將創下歷史最大跌幅，因其一款實驗性眼科藥物未能達到後期臨床試驗目標

美股開盤 | 三大指數升跌不一，閃迪升逾3%，Argenx SE漲近9%

老虎资讯综合

EyePoint公司治療年齡相關性眼病的藥物晚期臨床試驗失敗，股價暴跌

美股異動 | Argenx(ARGX.US)盤前升逾10% 自身免疫性肌炎藥物Vyvgart III期研究達主要終點

美股異動丨Argenx SE盤前大升逾7%，Efgartigimod治療肌炎III期試驗成功

復星醫藥子公司攜生物類似藥出海牽手全球仿製藥龍頭，鎖定四成銷售分成

每日经济新闻

復宏漢霖與山德士達成戰略合作

argenx SE（ARGX）宣佈Efgartigimod治療自身免疫性肌炎的3期ALKIVIA試驗取得積極結果

巴克萊上調安進目標價至380美元

復宏漢霖擬向山德士授權至多10款生物類似藥，國產生物藥國際化再進一步｜醫藥早參

每日经济新闻

復宏漢霖攜手Sandoz佈局生物類似藥首批3款產品落地

復星醫藥：控股子公司與Sandoz AG達成至多10款生物類似藥許可合作，首批3款產品首付款及里程碑款至多2.37億美元

Assembly股價上漲，因季度營收超出預期

中國銀河證券：實驗動物為創新藥研發剛需小鼠+猴雙主線高景氣

百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務不涉及創新藥研發

MacroGenics股價上漲，因吉利德支付了1000萬美元的里程碑款項

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/IBB/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"IBB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指數ETF-iShares Nasdaq","latestPrice":202.4,"timestamp":1789588800000,"preClose":202,"halted":0,"volume":1098798,"hourTrading":{"tag":"盘后","latestPrice":202,"preClose":202.4,"latestTime":"19:51 EDT","volume":4819,"amount":973909.5218,"timestamp":1789602686411,"change":-0.4,"changeRate":-0.001976,"amplitude":0.001976},"delay":0,"changeRate":0.0019801980198020084,"floatShares":50950000,"shares":50950000,"eps":6.311863,"marketStatus":"未開盤","change":0.4,"latestTime":"09-16 16:00:00 EDT","open":202.49,"high":204.1599,"low":200.98,"amount":222834762.01068002,"amplitude":0.015742,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":202,"sharesOutstanding":49450000,"nav":202.074365,"aum":10376518642.75,"dividendRate":0.001996,"bidAskSpread":0.000288,"preHourTrading":{"tag":"盘前","latestPrice":203.71,"preClose":202,"latestTime":"09:17 EDT","volume":108,"amount":21996.522,"timestamp":1789564649878,"change":1.71,"changeRate":0.008465,"amplitude":0.010149},"postHourTrading":{"tag":"盘后","latestPrice":202,"preClose":202.4,"latestTime":"19:51 EDT","volume":4819,"amount":973909.5218,"timestamp":1789602686411,"change":-0.4,"changeRate":-0.001976,"amplitude":0.001976},"volumeRatio":0.643087,"impliedVol":0.2493,"impliedVolPercentile":0.745},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","floatShares":50950000,"roa":"0.10%","roe":"24.54%","lyrEps":35.344796,"volumeRatio":0.643087,"shares":50950000,"dividePrice":0.404,"high":204.1599,"amplitude":0.015742,"preClose":202,"low":200.98,"week52Low":138.785,"pbRate":"1.27","psRate":"248.11","week52High":217.12,"institutionHeld":0,"latestPrice":202.4,"eps":6.311863,"divideRate":0.001996,"volume":1098798,"delay":0,"ttmEps":6.311863,"open":202.49,"prevYearClose":168.77,"prevWeekClose":202.93,"prevMonthClose":209.05,"prevQuarterClose":190.19,"fiveDayClose":205.49,"twentyDayClose":203.56,"sixtyDayClose":177},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"IBB","amount":0.011194,"announcedDate":"2026-09-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-18"},{"date":"2026-06-15","symbol":"IBB","amount":0.023774,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2026-03-17","symbol":"IBB","amount":0.121818,"announcedDate":"2026-03-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-17","defaultRemindTime":1773754200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-03-17","currency":"USD","dateTimestamp":1773720000000,"payDate":"2026-03-20"},{"date":"2025-12-16","symbol":"IBB","amount":0.183099,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-09-16","symbol":"IBB","amount":0.082843,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-19"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBB\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-26","recordDate":"2016-09-28","paymentDate":"2016-09-30","value":0.0858219,"currency":"USD"},{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.091903,"currency":"USD"},{"executeDate":"2017-03-24","recordDate":"2017-03-28","paymentDate":"2017-03-30","value":0.29898,"currency":"USD"},{"executeDate":"2017-06-27","recordDate":"2017-06-29","paymentDate":"2017-06-30","value":0.176803,"currency":"USD"},{"executeDate":"2017-09-26","recordDate":"2017-09-27","paymentDate":"2017-09-29","value":0.118654,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBB\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660416851","title":"藥代違規進入診療區域！湘雅二醫院發藥品「停用函」，艾力斯、賽諾菲、安進、康蒂尼四藥企上「黑榜」","url":"https://stock-news.laohu8.com/highlight/detail?id=2660416851","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660416851?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 09:48","pubTimestamp":1787104101,"startTime":"0","endTime":"0","summary":"湘雅二医院方面向澎湃新闻表示，院方确有发该“协办函”。据此次公布的协办函，对几家涉事药企的处理决定颇为严厉。近年来，医药代表违规已不仅是行业道德问题，而是监管重点。此次湘雅二医院将企业列入购销负面清单，正是医院端落地上述政策的缩影。湘雅二医院相关负责人表示，自国家在2020年底建立医药代表备案制度，医院就积极响应国家政策，并不断完善内部制度和执行流程。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787103396417327872","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","LU1057294990.SGD","IBBQ","BK4533","LU2242652126.USD","IE0009355771.USD","LU2468319806.SGD","LU0320765992.SGD","BK4581","BK4139","IE00B2B36J28.USD","688578","IE00BJT1NW94.SGD","LU2089984988.USD","IE0002141913.USD","LU2112291526.USD","BK4534","LU1571399168.USD","IBB","BK4599","BK4566","IE00BJJMRZ35.SGD","BBH","LU1061106388.HKD","LU1023059063.AUD","SG9999001440.SGD","BIB","PBE","AMGN","BK0239","LU0868494617.USD","IE00B4R5TH58.HKD","BK4588","IE00BFTCPJ56.SGD","TBXU","LU0109394709.USD","PJP","LU0122379950.USD","LU2242646821.SGD","LU0889565916.HKD","LU0289739699.SGD","LU1983299246.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192416297","title":"TScan Therapeutics披露：安進將終止與其研究合作及許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1192416297","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192416297?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 05:04","pubTimestamp":1787087050,"startTime":"0","endTime":"0","summary":"值得注意的是，安进作为全球领先的生物制药公司，此举无疑将对TScan Therapeutics的研发管线及未来战略布局产生深远影响。TScan Therapeutics方面表示，将仔细评估这一变化对公司在研项目及整体运营带来的潜在影响。对于TScan Therapeutics而言，此番变故或许意味着需要重新校准其研发路径，并探索新的合作机会或资金来源以继续推进其创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","LU0868494617.USD","LU1023059063.AUD","LU1057294990.SGD","LU2112291526.USD","IBBQ","LU0122379950.USD","LU1571399168.USD","LU0889565916.HKD","AMGN","PJP","BK4533","BK4599","IE0009355771.USD","SG9999001440.SGD","LU0289739699.SGD","LU2242652126.USD","BK4566","IBB","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4534","LU2089984988.USD","BIB","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4139","LU0109394709.USD","LU0320765992.SGD","BK4585","PBE","LU0058720904.USD","LU2468319806.SGD","LU1061106388.HKD","BK4588","BK4539","IE00BJJMRZ35.SGD","IE0002141913.USD","LU1983299246.USD","TCRX","BBH","LU2242646821.SGD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660491619","title":"吉利德科學(GILD)股票8月18日盤中上漲3.14%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660491619","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660491619?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 02:16","pubTimestamp":1787076999,"startTime":"0","endTime":"0","summary":"• 联邦法院禁令阻止了吉利德关键HIV药物的海外进口。\n• 强劲的基础业务营收增长与上调业绩指引提振了市场乐观情绪。\n• 肿瘤领域的战略投资及机构看涨期权活动的活跃支撑了股价的上涨势头。","market":"hk","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262115765-market-movers-gild-20260818","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1023059063.AUD","LU0823416689.USD","IBBQ","IE00B7SZLL34.SGD","LU2324357040.USD","LU0114720955.EUR","LU0320765992.SGD","IBB","IE00B19Z3581.USD","SG9999015978.USD","LU0058720904.USD","BK4550","BK4583","BIB","BK4566","LU0109394709.USD","LU1934455863.HKD","LU1037948897.HKD","LU1839511570.USD","SG9999015986.USD","LU0289739699.SGD","BK4578","GILD","BK4532","LU1571399168.USD","TBXU","BBH","LU1037948541.HKD","LU2089984988.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU1674673428.USD","SG9999015952.SGD","LU1430594728.SGD","LU1061106388.HKD","BK4585","LU1674673691.USD","LU2087621335.USD","MEDI","TMED","LU0965509101.SGD","LU2112291526.USD","LU1585245621.USD","LU1778281490.HKD","LU0965508806.USD","BMED","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660439442","title":"argenx SE(ARGX)股票8月17日盤中上漲16.67%：關鍵驅動因素揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=2660439442","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660439442?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 00:16","pubTimestamp":1786983373,"startTime":"0","endTime":"0","summary":"• Argenx 宣布其药物 VYVGART Hytrulo 在治疗肌炎的 3 期 ALKIVIA 研究中取得积极结果。\n• 该公司公布全年营收为 41.5 亿美元，净利润为 12.9 亿美元。\n• 分析师给予“买入”评级，平均目标价为 1083.77 美元。","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262112725-market-movers-argx-20260817","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0823416689.USD","IE00BFTCPJ56.SGD","BK4585","IE00BJT1NW94.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IBB","IE00B2B36J28.USD","BK4139","LU2324357040.USD","TBXU","BK4588","ARGX","IE0002141913.USD","FMED","IE0009355771.USD","LU0320765992.SGD","IE0034235188.USD","LU0109394709.USD","LU1983260115.SGD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660332334","title":"EyePoint股價料將創下歷史最大跌幅，因其一款實驗性眼科藥物未能達到後期臨床試驗目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2660332334","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660332334?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 22:15","pubTimestamp":1786976114,"startTime":"0","endTime":"0","summary":"BUZZ-EyePoint股价料将创下历史最大跌幅，因其一款实验性眼科药物未能达到后期临床试验目标最新动态8月17日-**EyePoint公司（EYPT.O）股价暴跌71%至4.17美元，有望创下有史以来最大单日跌幅，并跌至2025年4月以来的最低点**这家药物开发商表示，其实验性眼科药物Duravyu在针对湿性年龄相关性黄斑变性（视力丧失的主要原因之一）患者开展的晚期临床试验中，未能达到主要目标","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E101:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU1974910355.USD","LU2362541513.USD","BK4588","LU0053666078.USD","BK4007","LU2023250504.SGD","BK4585","LU0114720955.EUR","LU0823434583.USD","IBB","LU1917777945.USD","LU0058720904.USD","LU2106854487.HKD","LU0889565916.HKD","LU2468319806.SGD","BBH","IBBQ","LU2362541273.HKD","LU0109394709.USD","REGN","LU2362540622.SGD","LU0823434740.USD","LU0823416689.USD","TBXU","LU0289739699.SGD","LU0882574055.USD","LU2237438978.USD","LU0320765992.SGD","EYPT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137019504","title":"美股開盤 | 三大指數升跌不一，閃迪升逾3%，Argenx SE漲近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137019504","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137019504?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 21:32","pubTimestamp":1786973544,"startTime":"0","endTime":"0","summary":"8月17日，美股三大指数开盘涨跌不一，道琼斯指数跌0.23%，标普500指数涨0.04%，纳斯达克综合指数涨0.24%。美股存储股普涨，SK海力士、西部数据、闪迪涨超3%，美光科技、希捷科技涨超2%。OmniAb涨超23%，公司此前宣布与礼来达成3.7亿美元药物研发协议。Argenx SE涨近9%，Efgartigimod治疗肌炎III期试验成功。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","AGNG","LU0471298694.HKD","SPDN","FTEC","LU0820561909.HKD","TTXU","LU2360107168.USD","LU1712237335.SGD","BK4585","IE00B7KXQ091.USD","LU2236285917.USD","VGT","LU2361044865.SGD","ELIL","LU2286300806.USD","LU2237443895.HKD","LU2491050154.USD","HYNX","LU0082616367.USD","CNAV","LU0823416689.USD","LU2750360641.GBP","IE00B1XK9C88.USD","LU1035773651.USD","LU2756315664.SGD","BK4599","IE0005OL40V9.USD","LU1366333091.USD","LU2023251221.USD","WLDR","LU0154236417.USD","LU0708995401.HKD","PJP","SPXL","LU1983299246.USD","LU0203201768.USD","MMAX","IE0004445239.USD","LU1642822529.SGD","SKHZ","LU0106261372.USD","LU0162691827.USD","FHLC","LU2106854487.HKD","LU1823568750.SGD","SGXZ81514606.USD","IE00BJJMRX11.SGD","SDS","SKHY","LU1548497426.USD","IE00B5949003.HKD","LU2324357040.USD","LU0640476718.USD","BK4527","PPH","LU2112291526.USD","LU0203347892.USD","IE00BJLML261.HKD","IHE","IE00BN29S564.USD","SSO","LU0256863811.USD","LU1814569148.SGD","IE00B2B36J28.USD","IE00B4JS1V06.HKD","LU0256863902.USD","LU2468319806.SGD","SKHU","IE0034235188.USD","LU0240878834.USD","IE00BSNM7G36.USD","LU2168563687.JPY","DRMY","XLK","LU0097036916.USD","EGGY","BK4605","LU2102340556.USD","LU2462157665.USD","LU2089984988.USD","CHAT","GB00BDT5M118.USD","IETC","LU0859254822.USD","LU1804176565.USD","SG9999013999.USD","LU2290526834.HKD","AIQ","LU1815336760.USD","LU2456880835.USD","DOG","LU0792757196.USD","LU0820561818.USD","LU1280957306.USD","IE00BJJMRY28.SGD","LU2361045086.USD","LU1917777945.USD","FMED","IXJ","LU0456855351.SGD","LU1232071149.USD","SKHX","LU2264538146.SGD","LU0174119429.USD","LU1064131342.USD","SNDK","LU0689472784.USD","ARTY","LU0054578231.USD","LU0158827781.USD","LU0225283273.USD","LU2360106947.USD","LU0820562030.AUD","LU2111349929.HKD","SNDQ","DIA","LU1035775433.USD","LU0353189680.USD","LU0210536198.USD","LU0240877869.USD","LU2357627491.SGD","LU2750360997.AUD","IE00BWXC8680.SGD","LU1868836757.USD","SH","LU0081259029.USD","LU0444973449.USD","YSPY","LU1291159041.SGD","CNEQ","TMSL","SDOW","CHPS","LU2461242641.AUD","SG9999001424.SGD","QQQG","VOO","STX","LU1127390331.HKD","PTF","LU0345770308.USD","LU1069344957.HKD","SHOC","LU1235294995.USD","SPYM","LU0889565916.HKD","MUU","UDOW","IE00BFSS8Q28.SGD","SKHYV","LU0889565833.HKD","SK","LU2089284900.SGD","SMU00main","IE00BJT1NW94.SGD","TRUH","XLV","BK4554","UPRO","BK4553","LU2602419157.SGD","LU0133085943.USD","LU2360106780.USD","MEDX","IE0004445015.USD","LU0006306889.USD","SMH","SPXU","LU0316494557.USD","LU1778281490.HKD","SCHA","LU0006061336.USD",".DJI","LU0432979614.USD","SMAX","LU1551013342.USD","LU2028103732.USD","SGXZ51526630.SGD","SG9999018857.SGD","LU2491049909.HKD","MHIP","LU0964807845.USD","LU2108987350.USD","WUGI","LU1974910355.USD","LU2237443622.USD","LU2087625088.SGD","THNR","LU0320765059.SGD","HBMX","SOXX","SPY","LU1057294990.SGD","LU0058720904.USD","LU0203202063.USD","LU0683600562.USD","MIC","SGXZ57979304.SGD","LU1989764664.SGD","OZEM","MUD","SGXZ31699556.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","DISK","LU1674673428.USD","SG9999017495.SGD","LLY","LU1989771016.USD","LU0072461881.USD","CGGO","LU0266013472.USD","LU0642271901.SGD","LU1868836591.USD","FAI","BK4581","COWG","EFIV",".SPX","VHT","LU0234572021.USD","IE00B4R5TH58.HKD","LU2361044949.HKD","IXN","LU1852331112.SGD","AIS","LU2089283258.USD","SG9999015952.SGD","BK4505","LU2237443978.SGD","DMAX","LU1061106388.HKD","IE0009355771.USD","LEGR","MU","RXL","IYH","SG9999015986.USD","SG9999014914.USD","LU0882574055.USD","LU0957808578.USD","SG9999015945.SGD","WDNA","STX.AU","BK4512","IE00B19Z9Z06.USD","TBXU","LU0471298777.SGD","LU0719512351.SGD","JGRO","LU0476273544.USD","LU0417517546.SGD","IE00BK4W5M84.HKD","SNDG","LLII","LU2054465674.USD","LU0320765992.SGD","MULL","SG9999014898.SGD","IE0002270589.USD","LU2746668974.SGD","LU0158827948.USD","BOBP","LU1629891620.HKD","LU2746668461.USD","PSI","LU2168564065.EUR","TRFK","LU1670627923.USD","AIFD","07709","GDOC","LU1720051017.SGD","SPYU","LU2403377893.USD","LU0203345920.USD","LU0323591593.USD","CURE","LU1674673691.USD","SKUU","LU2237443382.USD","IE000M9KFDE8.USD","LU1145028129.USD","SOXQ","LU2265009873.SGD","MUYY","BK4141","IE00BKDWB100.SGD","BK4007","LU2063271972.USD","BAI","LU0385154629.USD","BK4575","LU2023250504.SGD","IBB","LU2271345857.HKD","USXF","LU0889566641.SGD","LU2250418816.HKD","LU2237438978.USD","LU1670628061.USD","LU0079474960.USD","LU0943347566.SGD","SG9999014906.USD","LU1983260115.SGD","LU2048586759.USD","BK4139","LU0114720955.EUR","BK4543","LU1023059063.AUD","LU1868837300.USD","IE0009356076.USD","LU1267930813.SGD","LU0094547139.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU2896262040.SGD","LU1861220033.SGD","LU2462591350.SGD","SG9999018865.SGD","IE00B775H168.HKD","SCHM","XNTK","FTXH","LU1868836914.USD","IE00B19Z9P08.USD","RULE","LU2168564495.EUR","LU2237443465.HKD","LU0345770993.USD","LU0823434583.USD","IE00BKPKM429.USD","BK4532","IE00BK4W5L77.USD","IE0002141913.USD","LU0238689110.USD","LU2168564222.USD","LU2931357623.SGD","LU1720051108.HKD","LU0444971666.USD","LU0882574139.USD","CANC","LU0061475181.USD","ARGX","LU1989764748.USD","BK4588","LU1868837136.USD","FDTX","LU0786609619.USD","MEDI","YMmain","LU0466842654.USD","JDOC","BK4566","LU2471134523.USD","SPYQ","IE00BJJMRZ35.SGD","LU0096364046.USD","HRTS","BK4579","LU0354030438.USD","LU2552382215.SGD","LU2756315318.SGD","FXL","LU0289739699.SGD","LU0963586101.USD","LU1267930730.SGD","SG9999001176.USD","LU2089985449.USD","LU0157215616.USD",".IXIC","SPYH","LU0672654240.SGD","SNXX","EMSF","LU0109392836.USD","LU0354030511.USD","LU2213496289.HKD","LU1069347547.HKD","LU2168564149.EUR","SGXZ99366536.SGD","LU0274383776.USD","LU1093756325.SGD","IE00BFSS7M15.SGD","SG9999014880.SGD","LU2471134879.HKD","BK4516","LU2237443549.SGD","FCUS","LU2458330243.SGD","MUZ","LU1046421795.USD","FSMD","LU2471134952.CNY","FTXL","LU0127658192.USD","OPTZ","DXD","LU2552382058.USD","LU2458330169.SGD","LU0353189763.USD","SG9999015978.USD","LU1093756168.USD","LU1803068979.SGD","LU2023250330.USD","LU2357305700.SGD","SKDD","LU2543165471.USD","SPUU","SKHA","ILDR","SNDU","DDM","LU0056508442.USD","LU2417539215.USD","LU2491050071.SGD","LU1861215975.USD","IE00B7SZLL34.SGD","HIBL","IE00B894F039.SGD","BK4533","ELIS","LU0198837287.USD","IE0034235303.USD","LU1979441026.SGD","CHPX","LU0109391861.USD","LU1316542783.SGD","LU1551013425.SGD","LU1988902786.USD","LLYZ","LU1366192091.USD","SPXS","WDC","BK4170","IVV","IE00B1BXHZ80.USD","SG9999001176.SGD","TMED","LU1914381329.SGD","WDCX","LU1323610961.USD","BK7142","LU2211815571.USD","LU2552382132.HKD","LU0122379950.USD","LU0787776722.HKD","LU0823434740.USD","QQQA","LU2471134796.USD","LU1623119135.USD","SNDC","LLYX","IE0001KFT4U8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848445","title":"EyePoint公司治療年齡相關性眼病的藥物晚期臨床試驗失敗，股價暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848445","media":"路透中文","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848445?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:14","pubTimestamp":1786965255,"startTime":"0","endTime":"0","summary":"EyePoint公司未能证明Duravyu在保护视力方面不比Eylea明显逊色。而在接受Eylea治疗的患者中，未出现此类情况。EyePoint的股价在早盘交易中跌至4.16美元。EyePoint计划于2027年上半年向美国FDA提交批准申请，具体取决于预计于今年晚些时候公布的第二项晚期临床试验结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E0O1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","LU2237438978.USD","IBBQ","LU2023250504.SGD","BBH","LU2106854487.HKD","BK4007","LU2468319806.SGD","TBXU","LU0320765992.SGD","IBB","LU2362540622.SGD","EYPT","LU0823434583.USD","LU0058720904.USD","LU2362541513.USD","LU0114720955.EUR","LU0889565916.HKD","LU0882574055.USD","BK4585","LU1974910355.USD","LU2089984988.USD","LU1917777945.USD","BK4139","LU0109394709.USD","OTLK","LU0289739699.SGD","LU2362541273.HKD","LU0823434740.USD","LU0823416689.USD","LU0053666078.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481020","title":"美股異動 | Argenx(ARGX.US)盤前升逾10% 自身免疫性肌炎藥物Vyvgart III期研究達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660481020?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 18:48","pubTimestamp":1786963699,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE0034235188.USD","BK4585","LU1983260115.SGD","LU0823416689.USD","FMED","LU0109394709.USD","LU2324357040.USD","IE0002141913.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","IBB","BK4505","BK4134","BK4588","IE00B4R5TH58.HKD","TBXU","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","ARGX","IE00BJT1NW94.SGD","LU0320765992.SGD","III","LU0889565916.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848605","title":"美股異動丨Argenx SE盤前大升逾7%，Efgartigimod治療肌炎III期試驗成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848605","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848605?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:37","pubTimestamp":1786959424,"startTime":"0","endTime":"0","summary":"Argenx SE(ARGX.US)盘前涨超7%，报913.38美元。消息面上，公司宣布，Efgartigimod在治疗自身免疫性肌炎的III期ALKIVIA试验中达到了主要终点。在52周时，与安慰剂相比，药物在总改善评分(TIS) 上实现了具有统计学和临床意义的改善。此次试验成功对Argenx意义重大，开辟新市场：自身免疫性肌炎在美国影响约10万人，其中IMNM约2万，DM约4万，这是一个尚未被满足的巨大医疗市场。公司计划为IMNM提交加速审批申请，并将与FDA讨论DM的申报可能性。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2324357040.USD","LU0109394709.USD","IE00B2B36J28.USD","IBB","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","BK4139","III","IE00BJT1NW94.SGD","BK4505","LU0889565916.HKD","BK4134","FMED","IE0034235188.USD","IE00BJJMRZ35.SGD","TBXU","ARGX","IE0002141913.USD","IE0009355771.USD","LU1983260115.SGD","BK4585","LU0823416689.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660866704","title":"復星醫藥子公司攜生物類似藥出海 牽手全球仿製藥龍頭，鎖定四成銷售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2660866704","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660866704?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:26","pubTimestamp":1786958770,"startTime":"0","endTime":"0","summary":"8月17日，复星医药（SH600196，股价24.01元，市值588.9亿元）公告披露，其控股子公司复宏汉霖与全球生物类似药龙头SandozAG于8月16日签订《合作框架协议》。双方约定，可就复宏汉霖至多10款单克隆抗体（mAb）和/或抗体偶联药物（ADC）生物类似药，开展海外区域的注册、商业化、开发、生产等许可合作，并已就首批3款产品达成具体商业条款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843260444.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843260444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBB","LU2322448957.HKD","BK0060","BK0028","02196","LU1992135399.USD","BK0187","BK1593","BK0239","BK0096","600196","BK4585","IE00B5TLWC47.USD","BK0012","BK1191","BK0183","LU2272731782.SGD","BK0188","LU2272731600.USD","XPH","BK4588","BK1515","LU2272731865.HKD","PPH","LU1992135472.HKD","BK0196","BK0175","LU2322448791.USD","LU2473716301.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660857514","title":"復宏漢霖與山德士達成戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2660857514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660857514?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:05","pubTimestamp":1786957508,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B5TLWC47.USD","BK4585","XPH","LU1992135399.USD","LU1992135472.HKD","LU2322448957.HKD","BK4588","LU2473716301.USD","LU2322448791.USD","LU2272731782.SGD","LU2272731865.HKD","IBB","PPH","LU2272731600.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660853994","title":"argenx SE（ARGX）宣佈Efgartigimod治療自身免疫性肌炎的3期ALKIVIA試驗取得積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2660853994","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660853994?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 16:43","pubTimestamp":1786956188,"startTime":"0","endTime":"0","summary":"该试验评估了皮下注射药物VYVGART Hytrulo在成人自身免疫性肌炎中的疗效，包括免疫介导的坏死性肌病和皮肌炎。在IMNM亚组分析中，治疗组同样展现出14.8分的显著改善。这是全球首个在没有任何批准疗法的IMNM领域取得统计学显著与临床意义改善的三期临床试验。自身免疫性肌炎属于罕见且高度致残的疾病，长久以来临床严重依赖大剂量激素和广谱免疫抑制剂。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303846","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","FMED","IE00BJT1NW94.SGD","IE0034235188.USD","BK4588","BK4585","IE00B2B36J28.USD","LU0320765992.SGD","IE0009355771.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0823416689.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","BK4505","LU1983260115.SGD","ARGX","IBB","LU2324357040.USD","BK4139","LU0109394709.USD","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660101358","title":"巴克萊上調安進目標價至380美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660101358","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660101358?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 11:05","pubTimestamp":1786935953,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["UUP","TBXU","BBH","BK4588","LU2112291526.USD","BK4533","BK4566","AMGN","BK4585","IBBQ","BIB","PBE","LU1571399168.USD","LU1983299246.USD","LU0289739699.SGD","BK4534","BK4139","IE00BJT1NW94.SGD","LU1061106388.HKD","LU2242646821.SGD","SG9999001440.SGD","LU0058720904.USD","LU1057294990.SGD","LU0320765992.SGD","UDN","PJP","IE00BJJMRZ35.SGD","LU0122379950.USD","LU0868494617.USD","LU1023059063.AUD","LU0889565916.HKD","IE0009355771.USD","BK4581","IE0002141913.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU2089984988.USD","IE00B2B36J28.USD","LU2242652126.USD","IE00BFTCPJ56.SGD","BK4599","LU2468319806.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660106203","title":"復宏漢霖擬向山德士授權至多10款生物類似藥，國產生物藥國際化再進一步｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2660106203","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660106203?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 09:33","pubTimestamp":1786930438,"startTime":"0","endTime":"0","summary":"过去一周（截至8月14日收盘），创新药板块震荡上行。打包医药全产业链的医药ETF（512120）上涨0.2%，聚焦A股创新药的生物医药ETF（159508）上涨1.77%，聚焦港股创新药的港股通生物科技ETF（159102）上涨0.12%。相关个股中，康龙化成上涨8.48%、药明康德上涨2.85%、恒瑞医药下跌3.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173842706171.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173842706171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2322448957.HKD","XPH","IBB","02696","BK4585","BK1515","LU2322448791.USD","PPH","HK0000306701.USD","HK0000320223.HKD","HK0000320264.USD","159839","LU2272731782.SGD","LU2272731600.USD","HK0000165453.HKD","159938","LU1992135472.HKD","LU2473716301.USD","09939","BK1574","HK0000306685.HKD","LU2272731865.HKD","IE00B5TLWC47.USD","BK4588","LU1992135399.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660110620","title":"復宏漢霖攜手Sandoz佈局生物類似藥 首批3款產品落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2660110620","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660110620?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 09:22","pubTimestamp":1786929720,"startTime":"0","endTime":"0","summary":"8月17日，复宏汉霖（02696）发布公告，公司于2026年8月16日与SandozAG达成战略合作框架协议，预计2026年可实现的开票金额总计不超过1.01亿元美元。此次合作开发最多10款单抗和/或ADC生物类似药相关产品，后续针对各个产品另行签订附属协议确定具体合作条款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173842662937.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173842662937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000306701.USD","HK0000306685.HKD","LU2272731600.USD","02696","BK4585","LU2473716301.USD","PPH","LU2272731782.SGD","LU2322448791.USD","LU2322448957.HKD","LU1992135472.HKD","HK0000320264.USD","BK1161","IBB","HK0000165453.HKD","BK4588","HK0000320223.HKD","XPH","IE00B5TLWC47.USD","LU1992135399.USD","LU2272731865.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660219103","title":"復星醫藥：控股子公司與Sandoz AG達成至多10款生物類似藥許可合作，首批3款產品首付款及里程碑款至多2.37億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660219103","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660219103?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 07:48","pubTimestamp":1786924110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2272731600.USD","LU2322448791.USD","IBB","IE00B5TLWC47.USD","LU1992135399.USD","BK4585","SILJ","LU1992135472.HKD","LU2272731865.HKD","SLVR","BK4588","XPH","LU2473716301.USD","LU2322448957.HKD","SLVX","LU2272731782.SGD","BK4210","PPH","SLJY","AG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659400001","title":"Assembly股價上漲，因季度營收超出預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2659400001","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659400001?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 23:25","pubTimestamp":1786721141,"startTime":"0","endTime":"0","summary":"BUZZ-Assembly股价上涨，因季度营收超出预期8月14日-** 药物研发公司Assembly Biosciences（ASMB.O）股价上涨4.6%，报31.32美元** ASMB第二季度与吉利德（GILD.O）合作研究的收入为1340万美元，高于去年同期的960万美元** 据LSEG数据显示，分析师此前平均预期营收为860万美元** 公司表示，营收增长包括针对吉利德合作项目下未来活动最新预估所作的510万美元补足调整** 报告显示第二季度每股亏损20美分，而市场预期为每股亏损65美分** 计入当日涨幅后，该股年初至今累计上涨11.8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL4S44B103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","ASMB","IBB","SG9999015952.SGD","LU0122379950.USD","LU1934455277.USD","LU2087621335.USD","BK4583","LU1037948541.HKD","LU0861579265.USD","LU0058720904.USD","IE00BSNM7G36.USD","LU1066051498.USD","TBXU","TMED","GILD","BK4585","LU1585245621.USD","LU0965509101.SGD","LU0965509283.SGD","LU2468319806.SGD","LU1066053197.SGD","LU2324357040.USD","LU0234570918.USD","LU1061106388.HKD","IE00B19Z3581.USD","LU0965508806.USD","BK4139","LU0289739699.SGD","LU1037948897.HKD","BK4566","BMED","BK4588","BK4532","IE00BZ1G4Q59.USD","IBBQ","BK4578","BK4568","LU0114720955.EUR","IE00B19Z3B42.SGD","BK4550","LU0889565916.HKD","BBH","LU2112291526.USD","BIB","LU0109394709.USD","MEDI","SG9999015986.USD","LU1839511570.USD","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中國銀河證券：實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601881","BK0188","BBP","WRND","BK4585","161027","PBE","BK4588","APXH","06881","LFSC","BK1147","GSKH","XLVI","SBIO","BK0276","IBB","BIOY","BK1564","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PBE","IBB","BIOY","SBIO","BK0102","BK4588","LFSC","BK4585","BK0216","XLVI","WRND","600721","APXH","GSKH","BBP","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658465479","title":"MacroGenics股價上漲，因吉利德支付了1000萬美元的里程碑款項","url":"https://stock-news.laohu8.com/highlight/detail?id=2658465479","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658465479?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 05:18","pubTimestamp":1786483082,"startTime":"0","endTime":"0","summary":"BUZZ-MacroGenics股价上涨，因吉利德支付了1000万美元的里程碑款项8月11日-** 药物开发商MacroGenics（MGNX.O）的股价在盘后交易中上涨3.8%，至4.07美元** 该公司表示，根据其与吉利德（GILD.O）就一项临床前双特异性项目（一种癌症疗法）达成的许可协议，已收到1000万美元的里程碑付款** 根据2022年签署的合作协议，MacroGenics与吉利德正在推进三个项目：处于临床阶段的抗癌疗法MGD024，以及两个处于临床前阶段的双特异性项目** MGNX仍有资格获得最高约16亿美元的额外开发、监管及商业里程碑付款** 今年以来，该公司股价已翻了一番多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S4481IH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","IE00BKVL7J92.USD","LU1571399168.USD","IE00BZ1G4Q59.USD","LU1674673428.USD","SG9999015952.SGD","GILD","LU1430594728.SGD","BK4578","BMED","SG9999015986.USD","IE00B7SZLL34.SGD","LU2089984988.USD","MGNX","LU1585245621.USD","BK4139","LU2468319806.SGD","LU1023059063.AUD","LU1066051498.USD","LU1674673691.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4585","IBB","LU0289739699.SGD","BBH","LU0965509101.SGD","LU1934455277.USD","LU0058720904.USD","BK4566","SG9999015945.SGD","TBXU","BK4550","LU0234570918.USD","BK4532","IE00B19Z3581.USD","LU1778281490.HKD","TMED","IE00BSNM7G36.USD","LU2087621335.USD","BK4588","LU1839511570.USD","LU2324357040.USD","LU0965508806.USD","LU0882574055.USD","IBBQ","LU0114720955.EUR","MEDI","LU1934455863.HKD","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}